PLEASANTON, Calif., April 7,
2022 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG) today
announced it will report financial results for the first quarter
2022 after market close on Wednesday, May 4,
2022. The company's management will webcast a corresponding
conference call beginning at 1:30 p.m.
Pacific Time / 4:30 p.m. Eastern
Time to discuss its results, business developments and
outlook.
Live audio of the webcast will be available on the "Investors"
section of the company website at: www.10xgenomics.com. The
webcast will be archived and available for replay for at least 45
days after the event.
About 10x Genomics
10x Genomics is a life science technology company building
products to interrogate, understand and master biology to advance
human health. The company's integrated solutions include
instruments, consumables and software for analyzing biological
systems at a resolution and scale that matches the complexity of
biology. 10x Genomics products have been adopted by researchers
around the world including in all of the top 100 global research
institutions as ranked by Nature in 2020 based on publications and
all of the top 20 global pharmaceutical companies by 2020 research
and development spend and have been cited in over 3,300 research
papers on discoveries ranging from oncology to immunology and
neuroscience. The company's patent portfolio comprises more than
1,300 issued patents and patent applications.
Disclosure Information
10x Genomics uses filings with the Securities and Exchange
Commission, its website (www.10xgenomics.com), press releases,
public conference calls, public webcasts and its social media
accounts as means of disclosing material non-public information and
for complying with its disclosure obligations under Regulation
FD.
Media Contact:
media@10xgenomics.com
Investor Relations
Contact:
investors@10xgenomics.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/10x-genomics-to-report-first-quarter-financial-results-on-may-4-2022-301520307.html
SOURCE 10x Genomics, Inc.